AR021578A1 - Formulacion en perlas de pravastatina con revestimiento enterico - Google Patents
Formulacion en perlas de pravastatina con revestimiento entericoInfo
- Publication number
- AR021578A1 AR021578A1 ARP990106243A ARP990106243A AR021578A1 AR 021578 A1 AR021578 A1 AR 021578A1 AR P990106243 A ARP990106243 A AR P990106243A AR P990106243 A ARP990106243 A AR P990106243A AR 021578 A1 AR021578 A1 AR 021578A1
- Authority
- AR
- Argentina
- Prior art keywords
- formulation
- pravastatin
- methacrylic acid
- enteric coating
- acid copolymer
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 title abstract 3
- 239000002702 enteric coating Substances 0.000 title abstract 3
- 238000009505 enteric coating Methods 0.000 title abstract 3
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 title abstract 3
- 229960002965 pravastatin Drugs 0.000 title abstract 3
- 239000011049 pearl Substances 0.000 title 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 abstract 3
- 229940117841 methacrylic acid copolymer Drugs 0.000 abstract 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 abstract 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 abstract 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 239000002610 basifying agent Substances 0.000 abstract 1
- 229910000019 calcium carbonate Inorganic materials 0.000 abstract 1
- 235000010216 calcium carbonate Nutrition 0.000 abstract 1
- 230000006866 deterioration Effects 0.000 abstract 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000004014 plasticizer Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 210000000813 small intestine Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Una formulacion en perlas de pravastatina con revestimiento entérico, la cual incluye pravastatina, opcionalmente un agente de basificacion tal como MgO oCaCO3, y un revestimiento entérico formado de un copolímero de ácido metacrílico el cual puedes er un copolímero de acrilato de metilo/ácido metacrílico o uncopolímero de metacrilato de metilo/ácido metacrílico, y plastificante tal como ftalato de dietilo y un espolvoreo de talco. La formulacion con revestimientoentérico tienen una buenaresist encia al deterioro en un pH menor que 3, pero tiene buenas propiedades de liberacion de fármaco en mayores que 4 y proporcionabiodisponibilidad incrementada y disminucion mejorada del LDL y los TGs comparado a las formulaciones depravastatina las cu ales no incluyen un revestimientoentérico y no proporcionan liberacion por todo el intestino delgado durante un tiempo de absorcion prolongado.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20654998A | 1998-12-07 | 1998-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR021578A1 true AR021578A1 (es) | 2002-07-24 |
Family
ID=22766876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990106243A AR021578A1 (es) | 1998-12-07 | 1999-12-07 | Formulacion en perlas de pravastatina con revestimiento enterico |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR021578A1 (es) |
| AU (1) | AU2161000A (es) |
| WO (1) | WO2000033821A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
| WO2001043723A1 (en) * | 1999-12-14 | 2001-06-21 | Biogal Gyogyszergyar Rt. | Novel forms of pravastatin sodium |
| EP1404303A4 (en) * | 2001-06-21 | 2006-03-15 | Andrx Pharmaceuticals Inc | STABLE PHARMACEUTICAL COMPOSITIONS BASED ON PRAVASTATIN |
| US9358214B2 (en) | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
| MXPA04006780A (es) | 2002-01-11 | 2005-06-08 | Athpharma Ltd | Formulaciones farmaceuticas de pravastatina y metodos para usarlas. |
| EP1905431A1 (en) * | 2002-01-11 | 2008-04-02 | Circ Pharma Research and Development Limited | Pravastatin pharmaceutical formulations and methods of their use |
| US20050089572A1 (en) * | 2002-03-22 | 2005-04-28 | Manoj Kumar | Controlled release drug delivery system of pravastatin |
| MXPA05002095A (es) * | 2002-09-03 | 2005-06-06 | Biovail Lab Int Srl | Formulaciones farmaceuticas de pravastatina y metodos de su uso. |
| EP1545503A4 (en) * | 2002-09-03 | 2007-12-12 | Circ Pharma Res And Dev Ltd | PHARMACEUTICAL FORMULATIONS AND METHODS FOR MODIFIED RELEASE OF STATINES |
| US8367111B2 (en) | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
| US8747895B2 (en) | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
| US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
| MX2007004741A (es) | 2004-10-21 | 2007-09-07 | Eurand Pharmaceuticals Ltd | Composiciones farmaceuticas con sabor enmascarado con formadores de poro gastrosolubles. |
| US20060105038A1 (en) * | 2004-11-12 | 2006-05-18 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions prepared by coacervation |
| US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
| DE102005032806A1 (de) * | 2005-07-12 | 2007-01-18 | Röhm Gmbh | Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten |
| US20070092573A1 (en) * | 2005-10-24 | 2007-04-26 | Laxminarayan Joshi | Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist |
| NZ600256A (en) | 2009-12-02 | 2014-05-30 | Aptalis Pharma Ltd | Fexofenadine microcapsules and compositions containing them |
| EP2343054A1 (en) | 2010-01-04 | 2011-07-13 | LEK Pharmaceuticals d.d. | Pellets and microparticles of pravastatin sodium and a process of making them |
| WO2016025762A1 (en) * | 2014-08-13 | 2016-02-18 | Cedars-Sinai Medical Center | Anti-methanogenic compositions and uses thereof |
| US10736871B2 (en) | 2015-04-01 | 2020-08-11 | Cedars-Sinai Medical Center | Anti-methanogenic lovastatin analogs or derivatives and uses thereof |
| CN111803462A (zh) * | 2020-07-15 | 2020-10-23 | 浙江诺得药业有限公司 | 一种普伐他汀钠肠溶片及其制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5158777A (en) * | 1990-02-16 | 1992-10-27 | E. R. Squibb & Sons, Inc. | Captopril formulation providing increased duration of activity |
| US5225202A (en) * | 1991-09-30 | 1993-07-06 | E. R. Squibb & Sons, Inc. | Enteric coated pharmaceutical compositions |
-
1999
- 1999-12-01 WO PCT/US1999/028375 patent/WO2000033821A1/en not_active Ceased
- 1999-12-01 AU AU21610/00A patent/AU2161000A/en not_active Abandoned
- 1999-12-07 AR ARP990106243A patent/AR021578A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000033821A1 (en) | 2000-06-15 |
| AU2161000A (en) | 2000-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR021578A1 (es) | Formulacion en perlas de pravastatina con revestimiento enterico | |
| BR0109943A (pt) | Composições farmacêuticas | |
| BR0302541A (pt) | Composições de formação de pelìcula poliacrìlica | |
| AR020610A1 (es) | Utilizacion de un copolimero de acido metacrilico de tipo c segun la farmacopea us national formulary usp/nf, como agente de desagregacion y el procedimiento de fabricaion de un comprimido con dicho copolimero | |
| AR027091A1 (es) | Forma de dosificacion de farmacos accionada por un hidrogel | |
| DE60226012D1 (de) | Geschmacksmaskierte pharmazeutische formulierungen | |
| ATE349207T1 (de) | Verstärkte wirkung mehrfach ungesättigter fettsäuren | |
| DK1198233T3 (da) | Sulfonamid- og sulfamidsubstituerede imidazoquinoliner | |
| PH12017502416A1 (en) | 17-hydroxyprogesterone ester-containing oral compositions and related methods | |
| ATE422350T1 (de) | Anisinsäure und glyceride enthaltende zusammensetzungen | |
| CY1108285T1 (el) | Σφαιροειδη, μεθοδος παρασκευης αυτων και φαρμακευτικες συνθεσεις | |
| BR0312782A (pt) | Composição para o tratamento de manchas | |
| IL155263A0 (en) | Pharmaceutical solutions of modafinil compounds | |
| TW200509863A (en) | Irradiation device for medical use | |
| AR028448A1 (es) | Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares | |
| ES2180729T3 (es) | Tratamiento terapeutico combinado de las patologias hiperproliferantes. | |
| PE20050441A1 (es) | Composiciones antibioticas | |
| MXPA04003540A (es) | Utilizacion de un copolimero para producir una forma galenica que contiene un peptido o proteina como agente activo. | |
| ITMI20022511A1 (it) | Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale. | |
| PL1666473T3 (pl) | Związki oparte na kwasie karboksylowym i kompozycje medyczne zawierające je jako składnik aktywny | |
| SE0001916D0 (sv) | Novel formulation | |
| ECSP993228A (es) | Formulacion de perlas de pravastatina con revestimiento enterico | |
| ATE303797T1 (de) | Orale fludara reinst formulierung mit schneller freisetzung des wirkstoffes | |
| PL350450A1 (en) | Vitamin d analogues and their pharmaceutical use | |
| AR040600A1 (es) | Composicion farmaceutica estable que comprende eritropoietina |